Episode Summary
Executive Summary: Rob Wiblin interviews Pardis Sabeti about using next-generation diagnostics, data systems, and rapid-response infrastructure to detect and contain contagious diseases and pandemics early. They discuss CRISPR-based Sherlock tests, high-throughput Carmen panels, metagenomic sequencing, the need for local trust and public-health coordination, and how these platforms could improve routine care, outbreak control, and future vaccine development.
Main Topics: Pandemic preemption via diagnostics: Sabeti argues that the biggest leverage against pandemics is early detection: identifying pathogens quickly, locally, and cheaply before they spread, while also improving routine care for common infectious diseases. Sherlock CRISPR diagnostics: The conversation explains how CRISPR-based diagnostics can detect specific viral sequences rapidly and read out results on paper or in simple formats, making point-of-care testing more feasible. Carmen multiplex testing platform: Carmen combines CRISPR with microfluidics to run thousands of assays simultaneously, enabling broad respiratory/pathogen panels from many samples at low per-test cost. Metagenomic sequencing as escalation: When targeted tests fail, sequencing everything in a sample can identify novel or unexpected pathogens, though Sabeti emphasizes that it is best used after cheaper, more targeted tests. Implementation, trust, and data infrastructure: Success depends on training frontline workers, connecting data in real time, protecting privacy, and creating systems that communities trust rather than top-down surveillance that could be misused. Funding, institutions, and scaling: They discuss the roles of governments, philanthropy, public health systems, and private industry in paying for and rolling out diagnostic platforms, with emphasis on building durable capacity rather than one-off COVID fixes. Personal resilience and scientific culture: Sabeti reflects on recovery from a severe 2015 car accident, lessons from fieldwork, the importance of humor and trust in teams, and why scientific work depends on people taking care of their bodies and each other.
Key Arguments: Early diagnosis is foundational to stopping outbreaks; without knowing what is making people sick, treatment and containment are guesswork. Pandemic-control tools should be platform technologies that work across many pathogens, not single-disease solutions. CRISPR diagnostics are powerful because they can be rapidly retargeted to new sequences and can produce simple, field-deployable readouts. Multiplexed testing is essential because many infections present similarly; a broad differential is often more useful than one-off tests. Metagenomic sequencing is valuable, but not as the first step for every case because it can create noise and is often more expensive than targeted panels. Public-health tools can fail through misuse, stigma, privacy violations, and lack of trust, so deployment must be local, transparent, and carefully designed. Investment in diagnostics and surveillance is economically justified because outbreaks and pandemics impose far higher costs than preventive testing systems. Training and coordination matter as much as technology; the best systems combine lab tools, data pipelines, and empowered frontline workers. A more altruistic approach to testing and vaccination benefits everyone because infectious diseases create network effects and externalities.
Data Points: Frontline workers trained: about 1,000 - Sabeti says her programs have trained roughly a thousand frontline workers in genomics, bioinformatics, diagnostics, and project management. PCR labs with FDA approval during COVID: 160 of 260,000 clinical labs - Used to illustrate how slowly U.S. lab capacity scaled up early in the pandemic. Additional labs testing without FDA approval: about 40 more - Alongside the 160 FDA-approved labs, only a small number others were able to test during the early COVID response. Carmen throughput: about 64,000 assays at once - A microfluidic implementation of Carmen could run this many assays simultaneously in early versions. Carmen reads: about 5,000 different reads - The same system could produce thousands of results across samples and targets. Reagent cost reduction: 300-fold - Sabeti says Carmen miniaturization reduced reagent cost per test by roughly 300 times. Carmen daily capacity: about 1,000 samples/day - The FDA-submitted version could process around a thousand samples per day on one machine. Sherlock/COVID development timeline: around 6 months for antigen tests - Used to contrast conventional antigen test development with sequence-based diagnostics. CDC/MDH training program: 2 week-long programs - One in genomics and one in bioinformatics, run for CDC and multiple state health departments. Cost of Ebola to local economies: about $42 billion - Sabeti cites this to argue the economic case for prevention and diagnostics. NFL COVID testing spend: $100 million - An example used in discussing inefficient, concentrated testing spending during COVID. NFL staff/team testing: 7,000 people - The scale of repeated testing in the NFL example. Cases found in NFL testing: a few hundred - Despite enormous spending, the testing did not stop outbreaks. Vaccine doses pledged by Biden administration: 500 million Pfizer doses - Mentioned near the end as a sign of improving global vaccine access. Public health department budget example: budget for about 20 samples - Sabeti describes departments of health as being so under-resourced that training often outpaces actual testing budgets.
Pivotal Quotes: "“If we can send a man to the moon and we can do all these things, we can combat infectious diseases on our planet.”" — Pardis Sabeti: Her case that pandemic-prevention infrastructure is ambitious but achievable. "“The technologies we need to stop Ebola ... are what you need to stop that common cold going through your kids’ daycare.”" — Pardis Sabeti: Explaining why platform diagnostics have value far beyond rare high-consequence outbreaks. "“Never confuse your faith that in the end you will prevail with the ability to face the most devastating facts of your current existence.”" — Pardis Sabeti: She uses the Stockdale paradox to describe scientific perseverance under uncertainty and failure.
Implications: The episode argues for building durable, platform-based infectious-disease infrastructure now: cheap diagnostics, real-time data, and trusted local public health systems. If funded well, these tools could reduce everyday illness and make future pandemics far easier to catch early.